Clinical development of viral vectored vaccines against MERS-COV

Clinical development of viral vectored vaccines against MERS-COV

Bibliographic Details
Main Authors:	Ewer, K, Folegatti, P, Bellamy, D, Mair, C, Alharbi, N, Lambe, T, Wright, D, Warimwe, G, Gilbert, S
Format:	Conference item
Published:	American Society of Tropical Medicine and Hygiene 2018

Similar Items

Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
by: Munster, V, et al.
Published: (2017)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
by: Alharbi, N, et al.
Published: (2017)

Viral vectors as vaccine platforms: from immunogenicity to impact
by: Ewer (nee Russell), K, et al.
Published: (2016)

Clinical advances in viral-vectored influenza vaccines
by: Sebastian, S, et al.
Published: (2018)

Clinical Advances in Viral-Vectored Influenza Vaccines
by: Sarah Sebastian, et al.
Published: (2018-05-01)

Viral vector vaccines
by: McCann, N, et al.
Published: (2022)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
by: Ewer (nee Russell), K, et al.
Published: (2017)

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
by: Folegatti, PM, et al.
Published: (2020)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
by: Folegatti, P, et al.
Published: (2021)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
by: Moreira Folegatti, P
Published: (2021)

Viral vector-based vaccines against SARS-CoV-2
by: Kenneth Lundstrom
Published: (2021-10-01)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
by: Katie Ewer, et al.
Published: (2017-12-01)

A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge
by: Jung-Eun Park, et al.
Published: (2022-06-01)

Viral vectors as vaccine platforms: Deployment in sight
by: Rollier, C, et al.
Published: (2011)

Viral vectors as vaccine platforms: deployment in sight.
by: Rollier, C, et al.
Published: (2011)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
by: Folegatti, P, et al.
Published: (2019)

Viral vectored transmission blocking vaccines against Plasmodium falciparum
by: Kapulu, M, et al.
Published: (2010)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
by: Wanbo Tai, et al.
Published: (2023-09-01)

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
by: Folegatti, PM, et al.
Published: (2020)

Efficacy and safety of a modified Vaccinia Ankara-NP+M1 vaccine combined with QIV in people aged 65 and older: a randomised controlled clinical trial (INVICTUS)
by: Butler, C, et al.
Published: (2021)

Viral vectored transmission blocking vaccines against <it>Plasmodium falciparum</it>
by: Sinden Robert E, et al.
Published: (2010-10-01)

Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2
by: Aline Baldo, et al.
Published: (2021-05-01)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
by: Pedro M. Folegatti, et al.
Published: (2021-03-01)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
by: Bosaeed, M, et al.
Published: (2021)

Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice
by: Arunkumar, G, et al.
Published: (2019)

Viral Vector Vaccines against Bluetongue Virus
by: Luis Jiménez-Cabello, et al.
Published: (2020-12-01)

Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge
by: McMahon, M, et al.
Published: (2019)

MERS-COV
by: Z. Memish
Published: (2014-04-01)

Novel bivalent viral-vectored vaccines induce potent humoral and cellular immune responses conferring protection against stringent influenza a virus challenge
by: Tully, C, et al.
Published: (2017)

Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques
by: Joseph Prescott, et al.
Published: (2018-02-01)

Prospects for a MERS-CoV spike vaccine
by: Yusen Zhou, et al.
Published: (2018-08-01)

MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination
by: Christian Meyer zu Natrup, et al.
Published: (2023-06-01)

The Protective Efficacy of Single-Dose Nasal Immunization with Cold-Adapted Live-Attenuated MERS-CoV Vaccine against Lethal MERS-CoV Infections in Mice
by: Heejeong Seo, et al.
Published: (2023-08-01)

Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice
by: Entao Li, et al.
Published: (2020-01-01)

Viral Vector Vaccines Against ASF: Problems and Prospectives
by: Rustam Kh. Ravilov, et al.
Published: (2022-03-01)

Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
by: Hansam Cho, et al.
Published: (2021-03-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
by: Pedro M. Folegatti, et al.
Published: (2019-05-01)

An optimised method for the production of MERS-CoV spike expressing viral pseudotypes
by: K. Grehan, et al.
Published: (2015-01-01)

Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology
by: Gilbert, S, et al.
Published: (2017)

MERS-CoV
by: Beuy Joob, et al.
Published: (2014-09-01)